Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion

This study is not yet open for participant recruitment.

Verified by Hadassah Medical Organization, September 2006

First Received: October 3, 2006 No Changes Posted

Sponsored by:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00383773

Purpose

Patients with Central Retinal Vein Occlusion will undergo vitrectomy, a small needle of about 71 micron will enter a branch retinal vein and TPA will be injected into the obstracted vein.

Condition	Intervention
Central Retinal Vein Occlusion	Procedure: Retinal endo vascular surgery

MedlinePlus related topics: Surgery

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:

Visual acuity
Amount of macular edema.

Estimated Enrollment:	10
Study Start Date:	October 2006
Estimated Study Completion Date:	October 2007

Detailed Description:

Patients with Central Retinal Vein Occlusion less than 6 month duration and reduction of vision to 6/21 will go OCT and FANG examinations.

Patient will be operated vitrectomy, and a branch retinal vein will be punctured by small needle and rTPA 200mcg/ml will be injected to the vein.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

crvo less than 6 month
Visual Acuity less than 6/21
No prior eye surgery except cataract.

Exclusion Criteria:

Retinal/iris neovascularization

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00383773

Contacts

Contact: Michael Halpert, MD.	00972507874385	halpert@cc.huji.ac.il
Contact: Hadas Lemberg, PhD	0097226777572	Ihadas@hadassah.org.il

Sponsors and Collaborators

Hadassah Medical Organization

Investigators

Study Chair:

Michael halpert

Hadassah Medical Organization

More Information

No publications provided

Study ID Numbers:	1yumbo-HMO-CTIL
Study First Received:	October 3, 2006
Last Updated:	October 3, 2006
ClinicalTrials.gov Identifier:	NCT00383773 History of Changes
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:

retinal vein occlusion
rTPA

Study placed in the following topic categories:

Embolism and Thrombosis
Embolism
Eye Diseases
Retinal Vein Occlusion
Vascular Diseases

Tissue Plasminogen Activator
Venous Thrombosis
Thrombosis
Retinal Diseases

Additional relevant MeSH terms:

Embolism and Thrombosis
Eye Diseases
Retinal Vein Occlusion
Vascular Diseases

Cardiovascular Diseases
Venous Thrombosis
Thrombosis
Retinal Diseases

ClinicalTrials.gov processed this record on May 07, 2009